There have been global and in particular, UK supply issues with Immunoglobulin preparations. There are also questions around cost effectiveness in some indications.
Intravenous Immunoglobulins (IVIG) are therefore subject to a national Demand Management Plan.
This consists of
- Guidance on which indications are considered appropriate for treatment with IVIG.
- A national database within which all patients must be registered.
- The collection of data on IVIG usage, wastage and patient outcomes.
This guideline applies to all staff who prescribe, dispense and administer human normal immunoglobulin. This may be for intravenous (IVIg) or subcutaneous (SCIg) use.
|Compiled by:||Lisa Jackson, Deputy Chief Pharmacist|
|Date Ratified:||September 2016|
|Date Issued:||March 2017|
|Review Date:||September 2018|
|Contact name:||Lisa Jackson, Deputy Chief Pharmacist|